PCVX · ISSUER CIK 1649094
Vaxcyte, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 6 Vaxcyte, Inc. insiders reported $0.00 of open-market purchases and $5.3M of sales on SEC Form 4.
↗6 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 8 of 8 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$5.3MInsider selling
−$5.3MNet open-market
Oct 7, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 7, 202616:08 | Oct 5, 2026 | PCVX | EVP, Chief Scientific Ofc, COO | S · Sell10b5-1 | $86.74 | −18,000 | 145,435 | -11% | −$1.6M | ||
| Oct 7, 202616:08 | Oct 5, 2026 | PCVX | EVP, Chief Scientific Ofc, COO | M · Exercise10b5-1 | $5.35 | +18,000 | 163,435 | +12% | $96K | ||
| Oct 7, 202616:07 | Oct 5, 2026 | PCVX | SVP, Finance & CAO | S · Sell10b5-1 | $86.74 | −19,000 | 27,860 | -41% | −$1.6M | ||
| Oct 7, 202616:07 | Oct 5, 2026 | PCVX | SVP, Finance & CAO | M · Exercise10b5-1 | $25.92 | +19,000 | 46,860 | +68% | $492K | ||
| Oct 2, 202616:05 | Oct 1, 2026 | PCVX | EVP, Chief Scientific Ofc, COO | S · Sell10b5-1 | $56.67 | −2,250 | 145,435 | -2% | −$128K | ||
| Oct 2, 202616:05 | Oct 1, 2026 | PCVX | EVP, Chief Scientific Ofc, COO | M · Exercise10b5-1 | $5.35 | +2,250 | 147,685 | +2% | $12K | ||
| Sep 9, 202617:56 | Sep 8, 2026 | PCVX | CHIEF EXECUTIVE OFFICER, Director | F · Tax | $60.36 | −17,056 | 429,902 | -4% | $1.0M | ||
| Sep 9, 202617:54 | Sep 8, 2026 | PCVX | PRESIDENT AND CFO | F · Tax | $60.36 | −7,155 | 95,316 | -7% | $432K | ||
| Sep 9, 202617:53 | Sep 8, 2026 | PCVX | Chief Technical Ops Officer | F · Tax | $60.36 | −7,651 | 68,085 | -10% | $462K | ||
| Sep 9, 202617:52 | Sep 8, 2026 | PCVX | SVP, Finance & CAO | F · Tax | $60.36 | −1,327 | 27,860 | -5% | $80K | ||
| Sep 9, 202617:46 | Sep 9, 2026from Sep 4, 2026 | PCVX | EVP, Chief Scientific Ofc, COO | S · Sell10b5-1 | $60.35 | −2,715 | 145,435 | -2% | −$164K | ||
| Sep 9, 202617:46 | Sep 8, 2026 | PCVX | EVP, Chief Scientific Ofc, COO | F · Tax10b5-1 | $60.36 | −5,459 | 146,769 | -4% | $330K | ||
| Sep 9, 202617:40 | Sep 4, 2026 | PCVX | Chief Medical Officer | A · GrantLate 5d | — | +52,632 | 52,632 | New | — | ||
| Sep 2, 202619:58 | Sep 1, 2026 | PCVX | CHIEF OPERATING OFFICER | S · Sell10b5-1 | $61.07 | −3,477 | 155,041 | -2% | −$212K | ||
| Sep 2, 202619:58 | Sep 1, 2026 | PCVX | CHIEF OPERATING OFFICER | M · Exercise10b5-1 | $5.35 | +2,250 | 158,518 | +1% | $12K | ||
| Sep 2, 202619:58 | Sep 2, 2026from Aug 31, 2026 | PCVX | CHIEF OPERATING OFFICER | F · Tax10b5-1 | $61.18 | −2,705 | 153,609 | -2% | $166K | ||
| Sep 2, 202619:57 | Sep 2, 2026from Aug 31, 2026 | PCVX | CHIEF EXECUTIVE OFFICER, Director | F · Tax | $61.20 | −6,289 | 446,958 | -1% | $385K | ||
| Sep 2, 202619:56 | Sep 2, 2026from Aug 31, 2026 | PCVX | PRESIDENT AND CFO | F · Tax | $61.18 | −2,705 | 102,471 | -3% | $166K | ||
| Sep 2, 202619:56 | Sep 2, 2026from Aug 31, 2026 | PCVX | Chief Technical Ops Officer | F · Tax | $61.28 | −1,020 | 75,736 | -1% | $63K | ||
| Sep 2, 202619:54 | Sep 2, 2026from Aug 31, 2026 | PCVX | SVP, Finance & CAO | F · Tax | $61.22 | −569 | 29,187 | -2% | $35K | ||
| Aug 5, 202619:01 | Aug 5, 2026 | PCVX | Chief Technical Ops Officer | S · Sell10b5-1 | $55.00 | −17,000 | 76,756 | -18% | −$935K | ||
| Aug 5, 202619:01 | Aug 5, 2026 | PCVX | Chief Technical Ops Officer | M · Exercise10b5-1 | $24.79 | +17,000 | 93,756 | +22% | $421K | ||
| Aug 5, 202616:59 | Aug 3, 2026 | PCVX | CHIEF OPERATING OFFICER | S · Sell10b5-1 | $53.86 | −2,250 | 157,541 | -1% | −$121K | ||
| Aug 5, 202616:59 | Aug 3, 2026 | PCVX | CHIEF OPERATING OFFICER | M · Exercise10b5-1 | $5.35 | +2,250 | 159,791 | +1% | $12K | ||
| Aug 5, 202616:58 | Aug 3, 2026 | PCVX | PRESIDENT AND CFO | S · Sell10b5-1 | $53.89 | −10,000 | 105,176 | -9% | −$539K | ||
| Aug 5, 202616:58 | Aug 3, 2026 | PCVX | PRESIDENT AND CFO | M · Exercise10b5-1 | $5.35 | +10,000 | 115,176 | +10% | $54K |